So why all the current fuss over population health and analytics? In my opinion three fundamental elements are driving our market.
You’ve probably already read a number of articles about HRSA’s proposed 340B Drug Pricing Program Omnibus Guidance and the expected impact of the proposed changes. Now, you need to act.
When it was announced that the Health Resources and Services Administration (HRSA) had withdrawn its long-awaited mega-reg, you may have momentarily breathed a sigh of relief.
Confused over the status of the 340B orphan drug exclusion? The last several months have been filled with continued controversy and back-and-forth legal action.